Transcatheter Mitral Valve Repair System Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2022 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Transcatheter Mitral Valve Repair System Market: By Indications (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By Product (Mechanical Valves, Bioprosthetic Tissue (Biological) Valves), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Transcatheter Mitral Valve Repair System Market size was valued at USD 1,025.3 million in 2021 and is poised to grow at a significant CAGR of 6.7% over 2022–2028. The most common anomaly in the world is mitral regurgitation, and the frequency of the condition is rising in the elderly population. According to research by the National Center for Biotechnology Information (NCBI), there are currently 1.3 million adult sufferers of mitral regurgitation in the United States. The need for transcatheter mitral valves is being driven by transcatheter mitral valve replacement (TMVR), which has become a therapeutic alternative for the treatment of mitral regurgitation in patients at high or prohibitive surgical risk. Furthermore, the prevalence of degenerative primary mitral regurgitation and ischemia functional secondary mitral regurgitation is driving the rising demand for transcatheter mitral valves. Transcatheter aortic valve replacement (TAVR) has been approved for patients of all risk groups due to developments in transcatheter technologies that have revolutionized how aortic valve disease is treated. Increased frequency of mitral valve disease among the elderly population is another effect of rising life expectancy in developed nations. However, due to anatomical limitations or higher surgical risks, traditional therapeutic techniques may not be appropriate for older persons. Medical researchers and the transcatheter medicines sector are proliferating to create a new transcatheter method for mitral valve replacement. Due to transcatheter treatment’s less intrusive nature, common risks associated with surgery can also be avoided, allowing for symptomatic alleviation without increasing early perioperative risk. Most patients with symptomatic severe mitral regurgitation are not candidates for conventional surgery because of their high-risk factors and the lack of data demonstrating how a procedure affects challenging outcomes. Additionally, the market is anticipated to grow in the upcoming years due to technical developments and the release of new mitral valves. Additionally, it is expected that the market will be driven by the growing elderly population and the rising need for more minor invasive procedures for high-risk patients during the estimated period. New market prospects are presented by increased healthcare spending and the advent of cardiovascular illnesses in developing nations.

Recent Market Developments:

In March 2022, Edwards Lifesciences received approval from the U.S. Food and Drug Administration (FDA) for its MITRIS RESILIA valve. It is a tissue valve replacement which is specifically designed for the heart’s mitral position.

In April 2020, Abbott received the CE Mark approval for its Tendyne Transcatheter Mitral Valve Implantation System and TriClip Transcatheter Tricuspid Valve Repair System under its structural heart device portfolio.

In September 2021, the U.S. Food and Drug Administration (FDA) approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Valves to boost treatment options for individuals with aortic or mitral valve disease.

Transcatheter Mitral Valve Repair System Market

MARKET SUMMARY
-
12.9%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 12.9%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Transcatheter Mitral Valve Repair System Market

  • The report on global dysphagia management market gives historical, current and future market sizes (US$ Mn) on the basis of product type, indication, distribution channel, and geography.
  • The dysphagia management market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Eisai Co. Ltd.
  • Becton
  • Dickinson and Company (BD)
  • AstraZeneca Plc.
  • Cipla Limited
Transcatheter Mitral Valve Repair System Market Dynamics

The rising number of people addicted to smoking is expected to impact the dysphagia market’s growth. Dysphagia is one of the most dangerous side effects of smoking cigarettes for a lengthy period. While tobacco usage kills nearly 6 million people each year, the rising prevalence of oropharyngeal cancer drives the dysphagia market forward. The market’s expansion is projected to be restrained by the side effects and pain of dysphagia medications and tubes. Long-term use of dysphagia medicines like proton pump inhibitors is linked to a higher risk of hip fracture due to decreased calcium and iron absorption, as well as an increased risk of opportunistic infections with S. pneumoniae and C. difficult due to weakened natural gut flora.


North-America Got Significant Share

Transcatheter Mitral Valve Repair System Market

The dysphagia management market in North America is likely to hold the highest revenue share in 2022, and in the following years, it is predicted to increase rapidly. While this can be ascribed to the growing number of pediatric populations in the region's developing countries, an increase in hospitals and retail pharmacies also contributes to dysphagia management options in these areas. Because of the rising prevalence of dysphagia and refined healthcare expenditure in this area, North America dominates the dysphagia market. Furthermore, the key players' increasing focus on novel technology is expected to accelerate the market's growth rate in this area. Asia-Pacific is predicted to expand throughout the forecast period due to the rising number of generic manufacturers and increasing healthcare expenditure in this region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The transcatheter mitral valve repair system market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Transcatheter Mitral Valve Repair System Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The transcatheter mitral valve repair system market is projected to expand at a CAGR of 6.7% during the forecast period

Abbott Laboratories, Biotronik Pvt. Ltd, Colibri Heart Valve, Edwards Lifesciences Corporation, HLT Medical, LivaNova Plc, Medtronic plc

North America is the fastest-growing region for transcatheter mitral valve repair system market


Report

Company Profile

  • Abbott Laboratories
  • Biotronik Pvt. Ltd
  • Colibri Heart Valve
  • Edwards Lifesciences Corporation
  • HLT Medical
  • LivaNova Plc
  • Medtronic plc
  • Neovasc Inc
  • Transcatheter Technologies GmbH
  • Venus Medtech, Inc

Description

Transcatheter Mitral Valve Repair System Market size was valued at USD 1,025.3 million in 2021 and is poised to grow at a significant CAGR of 6.7% over 2022–2028. The most common anomaly in the world is mitral regurgitation, and the frequency of the condition is rising in the elderly population. According to research by the National Center for Biotechnology Information (NCBI), there are currently 1.3 million adult sufferers of mitral regurgitation in the United States. The need for transcatheter mitral valves is being driven by transcatheter mitral valve replacement (TMVR), which has become a therapeutic alternative for the treatment of mitral regurgitation in patients at high or prohibitive surgical risk. Furthermore, the prevalence of degenerative primary mitral regurgitation and ischemia functional secondary mitral regurgitation is driving the rising demand for transcatheter mitral valves. Transcatheter aortic valve replacement (TAVR) has been approved for patients of all risk groups due to developments in transcatheter technologies that have revolutionized how aortic valve disease is treated. Increased frequency of mitral valve disease among the elderly population is another effect of rising life expectancy in developed nations. However, due to anatomical limitations or higher surgical risks, traditional therapeutic techniques may not be appropriate for older persons. Medical researchers and the transcatheter medicines sector are proliferating to create a new transcatheter method for mitral valve replacement. Due to transcatheter treatment’s less intrusive nature, common risks associated with surgery can also be avoided, allowing for symptomatic alleviation without increasing early perioperative risk. Most patients with symptomatic severe mitral regurgitation are not candidates for conventional surgery because of their high-risk factors and the lack of data demonstrating how a procedure affects challenging outcomes. Additionally, the market is anticipated to grow in the upcoming years due to technical developments and the release of new mitral valves. Additionally, it is expected that the market will be driven by the growing elderly population and the rising need for more minor invasive procedures for high-risk patients during the estimated period. New market prospects are presented by increased healthcare spending and the advent of cardiovascular illnesses in developing nations.

Recent Market Developments:

In March 2022, Edwards Lifesciences received approval from the U.S. Food and Drug Administration (FDA) for its MITRIS RESILIA valve. It is a tissue valve replacement which is specifically designed for the heart’s mitral position.

In April 2020, Abbott received the CE Mark approval for its Tendyne Transcatheter Mitral Valve Implantation System and TriClip Transcatheter Tricuspid Valve Repair System under its structural heart device portfolio.

In September 2021, the U.S. Food and Drug Administration (FDA) approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Valves to boost treatment options for individuals with aortic or mitral valve disease.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX